Multidisciplinary Pre-Congress Day and Young Investigators Workshop
| 11:00 – 13:00 | JOINT SESSION (with Czech, English and German interpretation) | Room: Club E
Chairs: E Müller-Kägi R E Matlary L Haverman |
|---|---|---|
| 11:00 – 11:15 | Welcome and Introduction | |
| 11:15 – 11:35 | Nurses Presentation: Ideal and real role of the haemophilia nurse – Czech experience |
V Cepelakova |
| 11:35 – 11:55 | Physiotherapists Presentation: Important aspects of paediatric health to become a healthy adult |
M Katzerova |
| 11:55 – 12:15 | Psychosocial Professionals Presentation: Preventing psychosomatic consequences in bleeding disorders |
P Buckova |
| 12:15 – 13:00 | Joint Case Discussion and Q&A | All disciplines |
| 13:00 – 14:00 | Lunch |
| 14:00 – 17:00 | NURSES SESSION (with Czech interpretation and German interpretation ) | Room: Club E |
|---|---|---|
| 14:00 – 15:30 | Session 1 – Explaining complex medical concepts to patients living with bleeding disorders | Chair:
E Müller-Kägi |
| 14:00 – 14:20 | What should nurses know regarding the coagulation cascade and new treatments? | M Albisetti |
| 14:20 – 14:35 | How to explain difficult issues to patients | M Nolan |
| 14:35 – 15:05 | Health literacy | K Sørensen |
| 15:05 – 15:15 | Q&A | |
| 15:15 – 15:30 | Break | |
| 15:30 – 16:15 | Session 2 – Innovative Approaches for Care Delivery | M Bedford |
| 15:30 – 15:45 | T- grow a model of communication for clinical intervention | M Friberg Birkedal |
| 15:45 – 16:00 | Long distance follow-up | S Grønhaug |
| 16:00 – 16:15 | Eight years of nurse-led clinics | M Kavanagh |
| 16:15 – 16:30 | Break | |
| 16:30 – 17:00 | Session 3 – Is there a future for haemophilia nursing? | M Kavanagh |
| 16:30 – 16:40 | No, there will be no future | M Bedford |
| 16:40 – 16:50 | Yes, there is a future | K Juusola |
| 16:50 – 17:00 | The audience decides |
| 14:00 – 17:00 | PHYSIOTHERAPISTS SESSION (with Czech interpretation and German interpretation) | Room: Club A |
|---|---|---|
| 14:00 – 15:00 | Session 1 | Chair:
P McLaughlin |
| 14:00 – 14:45 | Basics of radiological assessment in haemophilia for physiotherapists | H Marmery |
| 14:45 – 15:00 | Q&A | |
| 15:00 – 16:00 | Workshops* | Room: Club A |
| 15:00 – 15:45 | Workshop 1: Point of Care Ultrasound (with Czech and German interpretation) | M Timmer D Stephensen |
| 15:00 – 15:45 | Workshop 2: Strengthening strategies in paediatrics according to DNS (given in English only) |
Room: Club B K Ptakova |
| 15:45 – 16:00 | Q&A | |
| 16:00 – 17:00 | Workshops* | Room: Club A |
| 16:00 – 16:45 | Workshop 1: Point of Care Ultrasound (given in English only) | M Timmer D Stephensen |
| 16:00 – 16:45 | Workshop 2: Strengthening strategies in paediatrics according to DNS (with Czech and German interpretation) |
Room: Club B K Ptakova |
| 16:45 – 17:00 | Q&A |
*To encourage interaction during the Workshops, participants will be split into two groups. Half of the group will first attend Workshop 1, then Workshop 2 and the other half of the group will attend the Workshops in the reverse order.
| 14:00 – 17:00 | PSYCHOSOCIAL PROFESSIONALS SESSION (with Czech and German interpretation) | Room: Club D |
|---|---|---|
| 14:00 – 15:00 | Session 1 | |
| 14:00 – 14:45 | Differences between the present and future through the new treatments | G Golan |
| 14:45 – 15:00 | Q&A | |
| 15:00 – 16:00 | Session 2 | |
| 15:00 – 15:45 | The effect of bleeding disorders on the wider family and caregivers | C Burgess |
| 15:45 – 16:00 | Q&A | |
| 16:00 – 17:00 | Session 3 | |
| 16:00 – 16:45 | The effect of growing up with haemophilia into adulthood | A Torres-Ortuño |
| 16:45 – 17:00 | Q&A |
| 14:00 – 17:00 | YOUNG INVESTIGATORS WORKSHOP | Room: 220
M Makris |
|---|---|---|
| Interactive half-day workshop for clinical and translational researchers |
| 17:00 – 18:00 | Networking Reception |
IMPORTANT: Pre-Congress Day and Young Investigators Workshop registrations require a separate, additional fee and is not automatically included in the registration for the main congress.
EAHAD Congress
| Multidisciplinary Educational Session | Room: Congress Hall
Chairs: |
|
|---|---|---|
| 09:30 – 11:00 | Managing comorbidities in older patients with haemophilia | C Hermans R Klamroth F Sayers N Uitslager |
| 11:00 – 11:30 | Coffee Break |
| INDUSTRY SPONSORED SESSIONS | |
|---|---|
| 11:30 – 12:45 | Industry sponsored sessions |
| 12:45 – 13:45 | Lunch Break |
| 13:45 – 15:00 | Industry sponsored sessions |
| 15:00 – 15:30 | Coffee Break |
| 15:30 – 16:45 | Industry sponsored sessions |
| 16:45 – 17:15 | Coffee Break |
| 17:15 – 18:30 | Industry sponsored sessions |
| 18:30 – 19:30 | Welcome Reception |
EAHAD Congress
| 08:45 – 09:00 | WELCOME AND INTRODUCTION | Room: Congress Hall
J Blatny |
|---|
| 09:00 – 10:30 | SESSION 1: Gene therapy in haemophilia | Chairs: W Miesbach A Batorova |
|---|---|---|
| 09:00 – 09:30 | Current status of the gene therapy in haemophilia A and haemophilia B – 2019 update | J Pasi |
| 09:30 – 10:00 | How (much) can we pay for gene therapy in haemophilia? | P Cortesi |
| 10:00 – 10:30 | How can a patient choose between all of the available therapies? | D Page |
| 10:30 – 11:00 | Coffee Break/Poster Viewing |
| 11:00 – 12:30 | SESSION 2: Inhibitors – the major challenge in haemophilia treatment | Chairs: H Chambost E Zapotocka |
|---|---|---|
| 11:00 – 11:30 | Why and how do inhibitors develop in haemophilia A and B? | D Matino |
| 11:30 – 12:00 | What is the optimal treatment for a newly diagnosed PUP? | K Fijn van Draat |
| 12:00 – 12:30 | Novel agents for treatment of haemophilia with inhibitors | A Tiede |
| 12:30 – 13:30 | Lunch Break/Poster Viewing/EAHAD Annual General Meeting |
| 13:30 – 15:00 | SESSION 3: Rare bleeding disorders | Chairs: V Jimenez-Yuste M Penka |
|---|---|---|
| 13:30 – 14:00 | TFPI and Factor V short | E Castoldi |
| 14:00 – 14:30 | FVII deficiency – what does it mean for the patient and the treater? | A Batorova |
| 14:30 – 15:00 | Gene therapy for rare bleeding disorders | E Tuddenham |
| 15:00 – 15:30 | Coffee Break/Poster Viewing |
| 15:30 – 16:45 | SESSION 4: Clinical registries and Real World Data | Chairs: G Dolan Z Cermakova |
|---|---|---|
| 15:30 – 16:00 | The benefit of a national registry | J Blatny |
| 16:00 – 16:30 | The advantages and disadvantages of registries | F Rosendaal |
| 16:30 – 16:45 | Break |
| 16:45 – 17:45 | SESSION 5: Acquired bleeding disorders | Chairs: R Lassila J Gumulec |
|---|---|---|
| 16:45 – 17:15 | The coagulopathy of trauma | H Schöchl |
| 17:15 – 17:45 | Acquired von Willebrand syndrome | J Eikenboom |
| 19:00 – 23:00 | Networking Evening |
EAHAD Congress
| 07:30 – 08:30 | MORNING CLINICAL CASES | Room: Congress Hall
Chairs: |
|---|---|---|
| 4 x 15 min Clinical case presentations |
| 08:30 – 10:00 | SESSION 6: SLAM | Room: Congress Hall
Chairs: |
|---|---|---|
| OR03 | Unique inflammatory signature in hemophilic arthropathy: Epigenetic changes due to interaction between blood and fibroblast-like synoviocytes | S Mignot |
| OR04 | Psycho-social determinants on caregivers’ burden of children with haemophilia (results of the BBC study) | K Khair |
| OR05 | Until what age should we worry about inhibitors? New data from the PedNet Registry on 1038 PUPs with severe hemophilia A followed from the first until over 1000 exposure days | M van den Berg |
| OR06 | Improved survival of patients with hemophilia in the Netherlands in the 21st century | S Hassan |
| OR07 | Changing paradigma in Turkey: Plasma derived FVIII products have mostly preferred for PUP patients in severe hemophilia-A for last two years | K Kavakli |
| OR08 | Intracranial hemorrhage in hemophilia – a systematic review | A Zwagemaker |
| OR09 | The Web-Accessible Population Pharmacokinetics Service–Hemophilia (WAPPS-HEMO) contribution to tailoring treatment in children: examples for hemophilia A and B | C Hoi Ting Yeung |
| OR10 | Phase 2b trial of AMT-061 (AAV5-Padua hFIX): translation into humans of an enhanced gene transfer vector for adults with severe or moderate-severe hemophilia B | A Von Drygalski |
| OR11 | Phase 2/3 trial of subcutaneous engineered FVIIa Marzeptacog alfa (activated) in hemophilia A or B with inhibitors: Pharmacokinetics, pharmacodynamics, efficacy and safety | H Levy |
| OR12 | Safety analysis of concomitant use of rFVIIa and emicizumab in congenital haemophilia a with inhibitors: Experience from the HAVEN clinical programme | S Seremetis |
| 10:00 – 10:30 | Coffee Break/Poster Viewing |
| 10:30 – 11:30 | SESSION 7: Monitoring the treatment of haemophilia | Room: Congress Hall
Chairs: |
|---|---|---|
| 10:30 – 11:00 | Monitoring blood – induced joint damage in black and white | W Foppen |
| 11:00 – 11:30 | Monitoring the treatment of haemophilia: Role of clinical laboratory | C Novembrino |
| 11:30 – 12:00 | AROSENIUS LECTURE 2019 | Room: Congress Hall
Chairs: |
|---|---|---|
| Haemophilia in Africa | P de Moerloose | |
| 12:00 – 12:30 | Break |
| 12:30 – 13:15 | POSTER AND RESEARCH AWARDS | Room: Congress Hall
Chairs: |
|---|---|---|
| 12:30 – 13:00 | Reports from 2017 Research Grant winners | J Boender R Palla |
| 13:00 – 13:15 | Award presentations |
| 13:15 – 14:15 | SESSION 8: HOT TOPICS | Room: Congress Hall
Chairs: |
|---|---|---|
| OR13 | BIVV001– A novel, VWF-independent, extended half-life FVIII therapy: First-in-human safety, tolerability, and pharmacokinetics | K Knobe |
| OR14 | Incidence of inhibitors in previously untreated patients with severe haemophilia A treated with rFVIIIFc: the PUPS A-LONG study | C Königs |
| OR15 | Surgical procedures in persons with haemophilia A (PWHA) without inhibitors receiving emicizumab – Experience from the HAVEN 3 study | E Santagostino |
| OR16 | The role of antithrombin lowering in patients with hemophilia: Hemostatic control pre- and post-fitusiran dosing interruption | J Pasi |
| 14:15 – 14:30 | CLOSING REMARKS | J Blatny |
|---|---|---|
| 14:30 – 15:30 | Lunch |